MissionIR Articles
-
MissionIRNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Secures First Texas Electronic Monitoring Contract
SuperCom (NASDAQ: SPCB), has been awarded a new electronic monitoring contract by a juvenile probation agency in Texas, marking the Company’s first engagement in the state and expanding its U.S. footprint to 14 states since mid-2024. The agency selected SuperCom to replace a long-time incumbent provider and will deploy the Company’s PureSecurity(TM) platform under a…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with rare disorders that often lack FDA-approved treatments, demand for novel therapies continues to grow. Soligenix is advancing late-stage programs including HyBryte(TM) for cutaneous T-cell lymphoma,…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast
CNS Pharmaceuticals (NASDAQ: CNSP) was featured in a BioMedWire Podcast discussing its sharpened focus on glioblastoma multiforme (“GBM”), one of the deadliest and least treatable forms of cancer. In the interview, CEO John Climaco said of GBM, “Patients have very little hope. Our mission is to change that completely, and we think we have the drugs…
-
MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Forms Massimo AI Technology to Expand into Robotics Markets
Massimo Group (NASDAQ: MAMO) has established Massimo AI Technology Inc., a wholly owned subsidiary created to advance the company into industrial and service robotics while supporting its long-term technology roadmap. The new division will develop practical automation and warehouse-assistance platforms, build a dedicated robotics supply and manufacturing foundation, and leverage Massimo’s existing strengths in electric systems…
-
MissionIRNewsBreaks – Decent Holding Inc. (NASDAQ: DXST) Closes $8 Million Registered Offering of Class A Shares and Warrants
Decent Holding (NASDAQ: DXST), an established wastewater treatment services provider in China, closed its $8 million registered offering consisting of 13,333,333 Class A ordinary shares at $0.60 per share and warrants to purchase 26,666,666 additional shares at 110 percent of the offering price with a 120-day term. Gross proceeds totaled $8 million before expenses, and…
-
MissionIRNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Details Encouraging LP-184 Phase 1a Results Showing Durable Disease Control in Advanced Solid Tumors
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, reported additional details and clinical insights from its completed Phase 1a dose-escalation study of LP-184 along with highlights from a recent webinar. The study in 63 heavily pre-treated patients with advanced solid tumors met all primary endpoints…
-
MissionIRNewsBreaks – A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Reaches Agreement With Major Central American Grocer to Deploy Smart Cart Platform
A2Z Cust2Mate Solutions (NASDAQ: AZ), a global smart retail technology company, said it entered an agreement with a premium grocery retailer operating more than 50 stores in Central America to deploy the A2Z Cust2mate smart cart platform. Initial rollout is planned for early 2026 in two flagship locations, with the shared goal of expanding to…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy
Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare diseases affecting more than 30 million Americans and the urgent need for new therapies. The article spotlights Soligenix’s late-stage development of HyBryte(TM) (synthetic hypericin)…
-
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Amends IND to Advance NRX-101 With TMS for Depression Treatment
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it amended its Investigational New Drug filing for NRX-101 to include use of the drug in combination with Transcranial Magnetic Stimulation for depression, including suicidal depression. The update follows evidence suggesting NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in…
-
MissionIRNewsBreaks – Massimo Group (NASDAQ: MAMO) Adopts Bitcoin Treasury Strategy With Initial Purchases Underway
Massimo Group (NASDAQ: MAMO) said its Board approved adding Bitcoin as part of a long-term treasury reserve strategy, with initial purchases already begun and holdings to be disclosed in upcoming SEC filings or via Form 8-K. The Company said the program will be funded primarily through operating cash flows, with the option to use market instruments,…
-
MissionIRNewsBreaks – Stewards Inc. (OTC: SWRD) Appoints Scott McGowan Chief Marketing Officer
Stewards (OTC: SWRD), a diversified financial company operating across private credit, real assets and digital finance, appointed Scott McGowan as chief marketing officer to lead integrated marketing and communications as the Company expands its operating segments and advances toward a planned Nasdaq Capital Market uplisting. McGowan, formerly director of investor relations at InvestorBrandNetwork and previously…
-
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said the FDA has received its Abbreviated New Drug Application for KETAFREE(TM), a preservative-free intravenous ketamine formulation, deeming the submission “substantially complete” and assigning a July 29, 2026 review goal date. CEO Jonathan Javitt said KETAFREE is designed to provide a single-patient, preservative-free alternative to current multidose…
-
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Schedules Corporate Update Call for Dec. 2
NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, said it will host a corporate update conference call on Dec. 2, 2025, at 9 a.m. Eastern to review recent clinical, regulatory and operational developments. To view the full press release, visit https://ibn.fm/9WZCK About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing…
-
MissionIRNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Announces Leadership Changes as Board Appoints Robert Stubblefield Interim CEO
SEGG Media (NASDAQ: SEGG, LTRYW) said its Board terminated CEO, Secretary and President Matthew McGahan and removed him as Chairman, appointing CFO Robert Stubblefield as Interim CEO, Secretary and President and naming Marc Bircham Chairman. McGahan will remain a Director until his term expires at the upcoming annual meeting. The Company said the leadership transition…
-
MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21
NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present at NobleCon21 on Dec. 3 at 4:30 p.m. EST, offering an update on the company’s expanded focus in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions, as well as progress in generating clinical…
-
MissionIRNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software
HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when…
Search Articles
Latest Articles
- GlobalTech Corporation (GLTK) Advances Global Retail Expansion Through Planned Moda in Pelle Acquisition, Supporting AI-Driven Growth Strategy
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Committed to Responsible Development as Momentum Builds in the Ambler Mining District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Issues Shareholder Letter Highlighting 2025 Milestones and 2026 Outlook
- MissionIRNewsBreaks – Wearable Devices to Spotlight Neural Interface Breakthroughs and Smart-Glasses Innovations at CES 2026
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Spotlighted as Samarium Supply Risks Intensify